Novartis/Alcon Merger Clears FTC Hurdle With Minor Divestiture, But Shareholder Battle Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis sells its miotic drug Miochol-E to Bausch & Lomb to avoid anticompetitive charges; a Novartis legal expert says a subset of Alcon's board cannot veto the transaction.
You may also be interested in...
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.
Par Gets Pumped: Teva To Divest $200 Million Of Products To Acquire Cephalon
FTC requires Teva to sell its generic versions of Actiq and Amrix to Par; Teva will also supply Par with generic Provigil for one year.
As Alcon Shareholders Fight Back, Will Novartis Sweeten Its Merger Offer?
Independent Alcon shareholders have been holding out for months for a buyout offer from Novartis that is closer to what the latter firm is paying for the majority of the company